Solutions

Online Inquiry

Global Services. (Creative Biolabs Authorized)

Solid Tumor Targeting CAR-T Development Services through Chemokine-Axis Matching

Online Inquiry

Background Service What We Can Offer Workflow Special Service Highlights FAQs Contact

Overcome the barriers of poor CAR-T trafficking and an immunosuppressive tumor microenvironment with Creative Biolabs' Solid Tumor Targeting CAR-T Development Services. Through proprietary Chemokine-Axis Matching and TME remodeling strategies, we enhance CAR-T cell homing, infiltration, and sustained functional activity within solid tumors. Our integrated approach enables more durable anti-tumor responses and supports efficient translation from research to clinical development - unlocking the therapeutic potential of CAR-T cells in previously treatment-resistant solid tumors.

Introduction

CAR-T cell success in liquid cancers has not translated to solid tumors due to the highly complex, barricaded, and hostile TME. Ineffective T cell trafficking is the primary hurdle. Research shows that genetically engineering CAR-T cells to express specific chemokine receptors (e.g., CXCR2, CCR8) can precisely co-opt the natural chemokine system to direct them into the tumor site, a strategy supported by numerous preclinical findings demonstrating superior anti-tumor immune responses and enhanced overall survival in solid tumor models.

Ways to Advance CAR-T Cell Therapy for Solid Tumors. (OA Literature) Fig.1 Strategies for improving CAR-T cell therapy in solid tumors.¹

Creative Biolabs' CAR-T Development through Chemokine-Axis Matching

Our services are specifically designed to address the foundational failure point of most solid tumor CAR-T trials: inefficient T cell homing. By integrating detailed TME analysis with advanced genetic engineering, we provide you with high-quality, pre-validated CAR-T cell leads engineered for superior infiltration and function. Key capabilities:

Enhanced Homing Specificity: We analyze your target tumor's chemokine profile and engineer CAR-T cells to express the optimal corresponding receptor, ensuring targeted migration to the TME.
TME Barrier Degradation: We offer co-engineering strategies to enable CAR-T cells to deliver or express TME-modifying agents to break down the physical stroma, actively facilitating deep penetration.
Functional Longevity: We design CAR constructs with co-stimulatory domains and/or resistance elements to protect the T cells from the hostile, immunosuppressive signals within the tumor, maximizing their persistence and cytolytic activity.
Reduced Off-Target Risk: By reducing the required systemic cell dose through enhanced homing efficiency, we help mitigate peripheral toxicity, offering a crucial safety advantage for your clinical candidates.

Discover How We Can Help - Request a Consultation.

What We Can Offer

Understanding the dominant chemokines in a patient's tumor is critical for selecting the most effective CAR-T chemokine receptor match. We integrate the following mainstream technology platforms and experiments to ensure optimal Chemokine-Axis Matching and TME modification:

High-Throughput Ligand Screening	Utilizing bead-based multiplex assays and quantitative ELISA to generate a detailed, quantitative profile of chemokine and cytokine expression in patient-derived tumor tissue or cell line supernatant. This identifies the best homing axes.
Receptor Expression Optimization	Flow cytometry and molecular cloning platforms to monitor, validate, and optimize the stable surface expression of engineered chemokine receptors on primary T cells.
Multi-omics Analysis	Transcriptome sequencing: Quantifies chemokine mRNA in tumor and immune cells. Proteomic detection: Measures levels of secreted chemokines Spatial analysis: Maps chemokine distribution and tumor microenvironment infiltration
Data Processing and Visualization	Chemokine signature construction and classification. Receptor-ligand matching heatmaps and scoring models.

Work Process

The required starting materials include the scFv sequence and car backbone design for the primary antigen, tumor tissue, or cell lines with chemokine expression data, and client-provided PBMCs or T cells for initial testing.

Workflow of CAR-T Development through Chemokine-Axis Matching. (Creative Biolabs Original)

The final deliverables consist of the engineered plasmid or lentivirus supply, a detailed functional characterization report and assay data, and a validated CAR-T cell line ready for further development.

Types of Our CAR-T Development through Chemokine-Axis Matching

Chemokine Axis	Key TME Ligands Targeted	Therapeutic Application Focus
CXCL9/10/11-CXCR3 Chemokine-Axis Matching	CXCL9 (MIG), CXCL10 (IP-10), CXCL11 (I-TAC)	Cancers where T cell infiltration is associated with high endogenous CXCR3 ligand expression, often responsive to interferon-gamma modulation.
CXCL16-CXCR6 Chemokine-Axis Matching	CXCL16	Targeting cancers, particularly those of epithelial origin, that constitutively express CXCL16, offering a distinct homing pathway.
CXCL1/8-CXCR1/2 Chemokine-Axis Matching	CXCL1, CXCL8(IL-8)	Targeting common tumor environments that release pro-inflammatory chemokines, which often recruit suppressive cells but can be re-purposed to recruit anti-tumor CAR-T cells.
CCL19/21-CCR7 Chemokine-Axis Matching	CCL19, CCL21	Primarily used to enhance the persistence and positioning of T cells within tumor-draining lymph nodes and specialized TME structures before final infiltration.

Core Benefits

Precision Targeting

We analyze your tumor's unique chemokine profile to design a matching homing receptor, moving beyond generic CAR-T development.

Dual-Mechanism Design

We co-engineer T-cells for enhanced trafficking (via chemokine receptors) and TME resilience, addressing multiple barriers simultaneously.

Validated Migration

Our proprietary Transwell assays quantitatively measure migration efficiency early, enabling data-driven decisions before in vivo studies.

FAQs

How to select the right chemokine receptor?

Selection depends on your tumor's unique chemokine profile. Use our TME Chemokine Profiling Service for data-driven selection (e.g., CXCR2 or CCR8), avoiding trial-and-error.

Can CAR-T overcome physical TME barriers?

Yes. We offer TME Modification Co-Engineering, enabling CAR-T cells to express enzymes that degrade the extracellular matrix for enhanced tumor penetration.

Are chemokine receptor modifications safe?

Yes. Targeted homing concentrates CAR-T cells at the tumor site, potentially lowering systemic exposure. We perform thorough specificity testing to ensure a favorable safety profile.

How does this compare to systemic T-cell injection?

Systemic injection relies on passive distribution. Our Chemokine-Axis Matching provides active, directional homing, significantly increasing tumor T-cell concentration as shown in published studies.

Partner with Us

Creative Biolabs is dedicated to transforming the solid tumor landscape by pioneering CAR-T cell precision engineering. Our Solid Tumor Targeting CAR-T Development Services through Chemokine-Axis Matching ensure your therapy reaches its intended target effectively, safely, and functionally. We invite you to connect with our specialists to discuss your solid tumor target, utilize our TME profiling capabilities, or begin a personalized collaboration.

Reference

Zhang, Kai et al. "Bright future or blind alley? CAR-T cell therapy for solid tumors." Frontiers in immunology vol. 14 1045024. 24 Jan. 2023. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2023.1045024

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.